Categories: News

NYSE Content Advisory: Pre-Market Update + SEC Chair Atkins Encourages IPOs in NYSE Speech

NEW YORK, Dec. 3, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

- Advertisement -

Kristen Scholer delivers the pre-market update on December 3rd

- Advertisement -
  • Equities aim to extend Tuesday’s gains as traders anticipate Federal Reserve interest rate cuts, with majority of the market expecting a 0.25% reduction at next week’s final meeting of the year.
  • Forecasts point to a faster pace of rate cuts under a new Fed chair, with Kevin Hassett increasingly viewed as Donald Trump’s choice to succeed Jerome Powell.
  • Economists expect the ADP report to show 40,000 private-sector jobs added last month. Meanwhile, SEC Chairman Paul Atkins outlined plans to ease IPO rules for smaller firms and depoliticize shareholder meetings.

Opening Bell
Franklin Templeton Holdings Trust celebrates their active municipal bond ETFs

- Advertisement -

Closing Bell
Helios Technologies (NYSE: HLIO) celebrates the company’s 55th anniversary of founding

- Advertisement -

Click here to download the NYSE TV App

- Advertisement -

Video – https://mma.prnewswire.com/media/2837607/NYSE_Market_Update_Dec_3.mp4
Logo – https://mma.prnewswire.com/media/2581322/New_York_Stock_Exchange_Logo.jpg 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-advisory-pre-market-update–sec-chair-atkins-encourages-ipos-in-nyse-speech-302631788.html

- Advertisement -

Recent Posts

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration

Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast,…

3 hours ago

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

7 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

7 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

7 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

7 hours ago